Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14119943 | 0.91 | TYR (0.56) | TYR | |
| SCHEMBL19861459 | 0.90 | ALDH1A1 (0.42) | — | |
| SCHEMBL16027488 | 0.88 | TYR (0.48) | TYR | |
| SCHEMBL16027490 | 0.88 | TYR (0.48) | TYR | |
| SCHEMBL15942910 | 0.83 | TYR (0.47) | TYR | |
| SCHEMBL14120664 | 0.83 | TYR (0.60) | TYR | |
| SCHEMBL1661009 | 0.82 | TYR (0.53) | TYR | |
| SCHEMBL1661005 | 0.82 | TYR (0.53) | TYR | |
| SCHEMBL21159023 | 0.82 | TYR (0.53) | TYR | |
| SCHEMBL14119749 | 0.82 | TYR (0.53) | TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970353-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9890176-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890176-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-02-13 | — | — | US | disclosed |
| WO-2014165107-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TLR5, TLR1, MANBA | TYR 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.